Search results
Jun 27, 2024 · Eisai Announces Status Relating to Acquisition of Own Shares. Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act. June 28, 2024. “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China.
At Eisai Pharmaceuticals India Pvt. Ltd., we dedicate our work to realize Eisai's corporate concept of hhc (human health care). We are committed to increasing benefits to patients and the people in the daily living domain.
Eisai at a Glance. A Leading Global Research and Development-Based Pharmaceutical Company Headquartered in Japan. Established in 1941, Eisai is a pharmaceutical company operating globally in terms of R&D, manufacturing and marketing, with a strong focus on prescription medicines. Over 80 years of history.
Eisai Co., Ltd. is based in Tokyo, Japan, while its American subsidiary, Eisai Inc., is headquartered in Nutley, New Jersey. Eisai Inc. is led by Ivan Cheung as CEO. [14]
6 days ago · Eisai is a research-based human health care company that discovers, develops and markets phamaceutical products internationally. Learn more about Eisai today.
Eisai Pharmaceuticals India Pvt. Ltd. (EIL) was incorporated in March 2007. It is a subsidiary of global Japanese pharmaceutical company, Eisai Co., Ltd., based in Tokyo, Japan.
Eisai came to America in 1987 with one goal in mind: Create innovative new medicines to help patients, their families and caregivers. We’ve been breaking through ever since, with solutions and therapies that help improve the lives of the people we serve.
Eisai is a Human health care (hhc) company that seeks to discover and develop innovative therapies that can help satisfy unmet medical needs and contribute to the health and well-being of people worldwide.
EPAT’s precision medicine and diagnostics aim to improve therapeutic results with fewer side effects. Eisai combines brilliant scientists, advanced technology, and precision chemistry to improve health care. Discover what we're working on today.
Jan 7, 2023 · Jan 7 (Reuters) - The U.S. Food and Drug Administration on Friday approved the Alzheimer's drug lecanemab developed by Eisai Co Ltd (4523.T) and Biogen Inc (BIIB.O) for patients in the earliest...
